# FDA 483 - Martin T. Taylor, DO, PhD - September 27, 2022

Source: https://www.keypedia.com/records/483/martin-t-taylor-do-phd/c9c10ab5-879f-40d9-9342-6e58464f7c38

> FDA 483 for Martin T. Taylor, DO, PhD on September 27, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Martin T. Taylor, DO, PhD
- Inspection Date: 2022-09-27
- Product Type: drugs
- Office Name: Cincinnati District Office
- Summary: An FDA inspection of Martin T. Taylor, DO, PhD in New Albany, OH, revealed significant deviations from the investigational plan for protocol M15-736. Issues included enrolling an ineligible subject, failing to report serious adverse events to the sponsor in a timely manner, and allowing unqualified study coordinators to perform critical screening and adverse event assessments. These findings indicate serious concerns regarding the integrity and safety of the clinical trial conduct.

## Related Officers

- [investigator](https://www.keypedia.com/people/geoffrey-k-kilili/b00aeedf-95bd-4ccf-a23e-6e12e60249c4)

Company: https://www.keypedia.com/companies/martin-t-taylor-do-phd/69488d56-0ece-439d-ad0d-8db7beceea47

Office: https://www.keypedia.com/offices/cincinnati-district-office/b67a0c35-82e3-4176-9039-988378f65c22